Myomo (NYSEAMERICAN:MYO) (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.
Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America. The company provides training, fitting and ongoing support to clinicians and patients, while also securing reimbursement agreements with Medicare and private insurers. In addition to its core device offering, Myomo continues to invest in software enhancements and data analytics to improve patient outcomes and support clinician decision-making.
Founded in 2002 and headquartered in Cambridge, Massachusetts, Myomo emerged from research conducted at the Massachusetts Institute of Technology. Since its inception, the company has focused on translating advanced robotics technology into practical medical solutions. Myomo completed its initial public offering in 2014, enabling expanded clinical trials and commercialization efforts.
Looking ahead, Myomo is pursuing next-generation wearable orthoses that aim to reduce device weight, enhance battery life and broaden indications to other parts of the body. The company’s ongoing research and development efforts remain centered on improving quality of life for patients with neuromuscular impairments and advancing the field of medical robotics.
